The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: Implications for plasma viral load and intracellular DNA decline

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 750-756

  Kramer, Victor G ^a,b   Hassounah, Said ^a,b   Colby Germinario, Susan P ^a   Oliveira, Maureen ^a   Lefebvre, Eric ^c   Mesplède, Thibault ^a   Wainberg, Mark A ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Tobira Therapeutics Inc   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Antiretrovirals; Antiviral; Entry inhibitors

Indexed keywords

ANTIGEN P24; CELL DNA; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; MARAVIROC; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CULTURE MEDIUM; IMIDAZOLE DERIVATIVE; TAK-652;

ARTICLE; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR DOCKING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRION; VIRUS LOAD; CELL LINE; CULTURE MEDIUM; HIV INFECTIONS; ISOLATION AND PURIFICATION; MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS CULTURE;

ANTI-HIV AGENTS; CELL LINE; CLINICAL TRIALS, PHASE II AS TOPIC; CULTURE MEDIA; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; HIV INFECTIONS; HIV-1; HUMANS; IMIDAZOLES; LEUKOCYTES, MONONUCLEAR; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL LOAD; VIRUS CULTIVATION;

EID: 84928193808     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku451     Document Type: Article

References (28)

1. Wilen CB, Tilton JC, Doms RW. Molecular mechanisms of HIV entry. Adv Exp Med Biol 2012; 726: 223-42.
2. Grivel JC, Shattock RJ, Margolis LB. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med 2011; 9 Suppl 1: S6.
3. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-41.
4. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
5. Kramer VG, Schader SM, Oliveira Met al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother 2012; 56: 4154-60.
6. Baba M, Takashima K, Miyake H et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005; 49:4584-91.
7. Lalezari J, Gathe J, Brinson C et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatmentexperienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr 2011; 57: 118-25.
8. Lusso P, Cocchi F, Balotta C et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995; 69: 3712-20.
9. Hwang SS, Boyle TJ, Lyerly HK et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253: 71-4.
10. Sastry L, Xu Y, Cooper R et al. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther 2004; 15: 221-6.
11. Kramer VG, Varsaneux O, Oliviera M et al. Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr 2014; 67: 7-14.
12. Hu H, Nau M, Ehrenberg P et al. Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4T cells to HIV-1 infection. Blood 2013; 121: 1136-44.
13. Tan Q, Zhu Y, Li J et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013; 341: 1387-90.
14. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-12.
15. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31: 455-61.
16. Garcia-Perez J, Rueda P, Alcami J et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 2011; 286:33409-21.
17. Maeda K, Das D, Yin PD et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 2008; 381: 956-74.
18. Tanabe H, Ouellette AJ, Cocco MJ et al. Differential effects on human immunodeficiency virus type 1 replication by alphadefensins with comparable bactericidal activities. J Virol 2004; 78:11622-31.
19. Victoria JG, Lee DJ, McDougall BR et al. Replication kinetics for divergent type 1 human immunodeficiency viruses using quantitative SYBR green I real-time polymerase chain reaction. AIDS Res Hum Retroviruses 2003; 19:865-74.
20. Brelot A, Heveker N, Pleskoff O et al. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 1997; 71: 4744-51.
21. Liu R, PaxtonWA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
22. Doranz BJ, Lu ZH, Rucker J et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997; 71: 6305-14.
23. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 2001; 82: 1807-14.
24. Huang CC, Lam SN, Acharya P et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007; 317: 1930-4.
25. Biscone MJ, Miamidian JL, Muchiri JM et al. Functional impact of HIV coreceptor-binding site mutations. Virology 2006; 351: 226-36.
26. Brelot A, Heveker N, Montes M et al. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 2000; 275: 23736-44.
27. Baba M, Miyake H, Wang X et al. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 2007; 51: 707-15.
28. Garcia-Perez J, Rueda P, Staropoli I et al. Newinsights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 2011; 286: 4978-90.